Earnings call transcript: Americas Silver sees stock drop despite production gains in Q4 2025

Americas Gold and Silver reported FY2025 revenue of $118M (+18% YoY) and attributable silver production of 2.65M oz (+52% YoY) but posted a wider net loss of $87M (vs. $49M in 2024), triggering a 16.54% share drop to $5.43 and near its 52-week low. All-in sustaining cost was $33/oz; management guided 2026 consolidated silver production of 3.2-3.6M oz at AISC $30-$35/oz with consolidated CapEx $90-$120M (exploration $15-$20M). Company closed a $133M bond financing to fund Crescent acquisition; market cap reported at $1.64B and P/E 9.76. Operational progress (Crescent integration, Galena upgrades, expanded exploration program) is positive but financial losses and high costs are weighing on investor sentiment.

Analysis

The market punished USAS for headline accounting and cash-flow optics rather than the operational inflection the company described; a $87m net loss and a $133m bond close create a near-term liquidity narrative that overwhelms improvement in production and the multi-year path to lower AISC. Second-order: high institutional ownership (reported jump to ~65%) plus index inclusions increases correlation with silver peers and reduces effective float — meaning forced rebalancing and block selling can amplify downside in weeks, even if fundamentals improve over quarters.

Operationally the optionality is asymmetric: byproduct pathways (antimony JV, new offtakes with Teck/Ocean Partners) and a large 64k m underground drill program can meaningfully compress AISC from $33 toward the $30 mid-point of guidance if conversion and processing scale on plan. That’s a multi-quarter to multi-year value driver, not a near-term de-risk — paste plant (timed for later 2026) and Coeur/No.3 shaft upgrades (Q2 2026) are binary catalysts that matter to volumes, not immediate profit.

Tail risks cluster around execution and financing: missed shaft/paste milestones or higher-than-guided capex ($90-120m) could force dilution or covenant stress on the December bond within 12-18 months; conversely successful delivery plus incremental high-grade discoveries (34, 149, 520 veins) could re-rate the stock sharply because reserve grade (~500+ g/t) is already top-tier. Watch calendar: next 90 days for Q2 operational sequencing (shaft day outage), and Q4 for paste plant and byproduct revenue ramp — these are the primary catalyst windows to move valuation materially.

Key Decisions for Investors

• Tactical hedge/short-term trade — USAS (short / put): buy 6–10 week ATM puts on USAS (e.g., Apr–Jun 2026 maturities) or establish a small directional short into any bounce. Rationale: market technicals and concentrated institutional ownership can drive further downside into Q2 shaft work; reward if shares revisit $3–4 range within weeks; risk = option premium or borrow cost on short.
• Core asymmetric long — USAS (long equity or long-dated call spread): establish a V-shaped exposure sized 1–3% of book by buying shares up to $5.50 or buying a Dec-2027 $7/$12 call spread. Target: $9–12 within 12–24 months if guidance execution, Crescent integration and antimony monetization occur; downside: stop-loss at $3.20 (~40%); trade captures operational leverage while limiting dilution risk with spread structure.
• Event-driven long — UAMY (long equity): allocate a smaller tactical stake (0.5–1% of book) in UAMY to play JV/antimony optionality over 6–12 months. Rationale: direct beneficiary of antimony processing ramp and higher byproduct pricing; target 30–50% upside on successful JV milestones; set 25% stop-loss for execution and commodity-demand risk.
• Monitoring trade — TECK (watch/optional small long): no immediate position but set alerts for Teck reporting or offtake revenue recognition tied to USAS. If Teck begins to recognize material incremental revenue from the offtake (quarterly cadence), consider a small long (0.5% book) as a risk-mitigated play on accelerated byproduct cash flow; upside limited but lower risk given Teck’s scale.